Navigation

Costing tools

Costing tools are normally provided for each technology appraisal, quality standard, medical technology, diagnostic technology, clinical guideline and public health guidance. Costing tools are not provided for interventional procedures.

Types of costing tool

NICE provides five types of costing tool:

  • national cost reports summarise the national estimate cost and discuss the assumptions made when estimating the financial impact of implementing the guidance. For technology appraisals, the report is incorporated into the costing template.
  • costing templates support estimating the local cost of implementing guidance. and public health guidelines. These templates allow individual NHS organisations and local health economies to quickly assess the impact guidance will have on local budgets. A video tutorial explaining how to use the costing templates is available in Windows Media Player and Quick Time format.
  • business case. It presents the financial costs and benefits of implementing guidance.
  • cost impact and commissioning assessment for NICE quality standards
  • costing statements are used when cost impact is considered to be minimal to explain why the cost impact is not considered to be significant.
  • NICE support for commissioners and others using the quality standard

All guidance published since January 2005 has costing tools. Costing tools currently available are listed below.

Further information on the methodology for developing costing tools.

Results 81-100 of 511

Ref Title
TA218 Myelodysplastic syndromes - azacitidine: costing template
TA217 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine: costing template
TA216 Leukaemia (lymphocytic) - bendamustine: costing template
TA215 Renal cell carcinoma (first line metastatic) - pazopanib: costing statement
TA214 Breast cancer - bevacizumab (in combination with a taxane): costing statement
TA213 Schizophrenia - aripiprazole: costing statement
TA212 Colorectal cancer (metastatic) - bevacizumab: costing statement
TA211 Prucalopride for chronic constipation in women: costing template
TA209 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib: costing statement
TA208 Gastric cancer (HER2-positive metastatic) - trastuzumab: costing template
TA204 Osteoporotic fractures - denosumab: costing statement
TA203 Diabetes (type 2) - liraglutide: costing template
TA202 Chronic lymphocytic leukaemia - ofatumumab: costing statement
TA200 Hepatitis C - peginterferon alfa and ribavirin: costing template
TA199 Psoriatic arthritis - etanercept, infliximab and adalimumab: costing statement
TA197 Atrial fibrillation - dronedarone: costing template
TA196 Gastrointestinal stromal tumours - imatinib (adjuvant): costing statement
TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor and TA198 Rheumatoid arthritis - tocilizumab: costing template
TA193 Leukaemia (chronic lymphocytic, relapsed) - rituximab: costing template & report
TA192 Lung cancer (non-small-cell, first line) - gefitinib: costing template

This page was last updated: 31 August 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.